Propofol-based intravenous anesthesia is associated with improved survival outcomes after major cancer surgery
Starting on:
Jul 12, 2024
Ending on:
Jul 12, 2024
Moderator(s):
Dr. SAMUEL NJIHIA
Dr
Venue:
KUTRRH
Max Credits:
3 Points

Provider:
Kenyatta University Teaching and Referral Hospital
Claim Points

Propofol-based intravenous anesthesia is associated with improved survival outcomes after major cancer surgery

Starting on:
Jul 12, 2024
Ending on:
Jul 12, 2024
Venue:
KUTRRH

Description

Propofol-based TIVA results in lower mortality rates after cancer surgery.

Objectives

There is an expanding body of evidence that analgesic, anaesthetic, and other perioperative interventions may affect rates of recurrence, return to intended oncological treatment (RIOT) after surgery, and overall survival in cancer patients. Opioids and volatile anesthetics have been implicated in angiogenesis and immunosuppression. Inhalational agents increase tumor growth factors such as HIF1α and insulin like growth factor,which promote tumor cell growth, invasion and migration. In contrast, propofol appears to decrease HIF1α and displays antioxidant and anti-inflammatory properties.

Presenters

  1. Dr. J JANAI
    Dr

Search For CPD Activity